Transmedics Group Inc
NASDAQ:TMDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Transmedics Group Inc
NASDAQ:TMDX
|
US |
|
S
|
Shandong Link Science and Technology Co Ltd
SZSE:001207
|
CN |
|
C
|
Chipotle Mexican Grill Inc
XETRA:C9F
|
US |
|
Stove Kraft Ltd
NSE:STOVEKRAFT
|
IN |
|
I
|
Indomobil Multi Jasa Tbk PT
IDX:IMJS
|
ID |
Transmedics Group Inc
TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists.
Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.
TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists.
Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.
Revenue Growth: TransMedics reported Q4 2025 revenue of $160.8 million, up 32% year-over-year and 12% sequentially; full-year 2025 revenue was $605.5 million, up 37% from 2024.
Strong Profitability: Q4 operating profit was $21.3 million (13.2% margin), and full-year operating profit was $108.6 million (18% margin); net income for the year surged to $190 million, aided by a tax benefit.
Transplant Volume Expansion: OCS transplants drove overall U.S. liver, heart, and lung transplant volumes up for a third consecutive year, with OCS now used in 26% of all such U.S. transplants, up from 20% in 2024.
2026 Guidance Raised: Revenue guidance for 2026 set at $727–$757 million, representing 20–25% growth over 2025, which is above prior expectations.
Margin Outlook: 2026 operating margin expected to be up to 250 basis points below 2025 levels due to increased R&D and growth investments, but management expects long-term margin expansion.
Key Programs & Trials: Progress highlighted in OCS Heart (ENHANZE trial), OCS Liver, and de novo Lung programs; new kidney platform (Gen 3.0) and European NOP model launches targeted.
International Expansion: Early traction in Europe, particularly Italy, with plans to double the addressable market, though initial pace may be moderate as logistics and support are built out.